Evidence map›Paper›PMID 41879603›Full record

ArticleJACC. Case reports2026

Preventing Inadvertent Cannulation Into the Vein of Marshall With a Useful Fluoroscopic Landmark.

Tomonobu Yanase, Nobuhiko Ueda, Shumpei Mori, Mitsuru Wada, Kohei Ishibashi, Kengo Kusano

Abstract readCase Reports
In one paragraph

Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tomonobu YanaseDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.
Nobuhiko UedaDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan. Electronic address: rabbitueda2003@ncvc.go.jp.
Shumpei MoriDavid Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California, USA.
Mitsuru WadaDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.
Kohei IshibashiDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.
Kengo KusanoDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCoronary sinus (CS) injury is a potentially serious complication during left ventricular lead implantation. Its risk may be reduced by recognizing atypical guidewire trajectories. CASE SUMMARY: A 71-year-old man with wild-type transthyretin cardiac amyloidosis underwent implantation of a cardiac resynchronization therapy device. During left ventricular lead placement, CS dissection occurred owing to the cannulation of a guiding catheter into the vein of Marshall (VOM) via an inadvertent guidewire. The patient remained hemodynamically stable, the CS dissection resolved spontaneously, and the procedure was completed successfully. DISCUSSION: The VOM courses between the left atrial appendage and the left pulmonary veins. The third mogul, which corresponds to the left atrial appendage, may serve as a useful anatomical landmark to indicate inadvertent guidewire entry into the VOM. TAKE-HOME MESSAGE: Identifying the third mogul on anteroposterior fluoroscopic view could facilitate early detection of inadvertent guidewire entry into the VOM and help prevent coronary venous complications.

Indexed as

anteroposterior fluoroscopic viewcardiac resynchronization therapycoronary sinus dissectionleft atrial appendageleft ventricular lead

Identifiers

PMID41879603
PMCPMC13130889

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.